Assembly Biosciences Q2 2024 net loss $11.2M; cash runway into Q1 2026

ASSEMBLY BIOSCIENCES, INC.

2024-Q2 EPS reported -$3.64 revenue$14,318,000

Cash, equivalents and marketable securities $109.2M as of June 30, 2024, down from $113.0M at March 31, 2024.
Revenue from Gilead collaboration $8.5M in Q2 2024 (vs. $0 in Q2 2023); R&D expenses $16.3M (up from $12.5M).
Net loss $11.2M ($1.98 per share) vs. $16.9M ($3.88) in Q2 2023; net loss improved on higher revenue.
Phase 1a/b dosing initiated for ABI-5366 (genital herpes) and Phase 1b for ABI-4334 (chronic HBV infection).
Two additional candidates (ABI-1179, ABI-6250) expected to enter clinic by end of 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.